Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy

Ann Neurol. 2002 Jun;51(6):790-3. doi: 10.1002/ana.10210.


We studied the impact of cerebral amyloid angiopathy on tissue plasminogen activator-induced cerebral hemorrhages in APP23 transgenic mice. Results show that the intravenous administration of tissue plasminogen activator in APP23 mice leads to an increase in cerebral amyloid angiopathy-associated microhemorrhages and can provoke parenchymal and subarachnoidal hematomas. We conclude that cerebral amyloid angiopathy is a risk factor for cerebral hemorrhage caused by tissue plasminogen activator administration in mice and stress the need for more comprehensive studies of the relation between cerebral amyloid angiopathy and tissue plasminogen activator-induced cerebral hemorrhages in elderly and Alzheimer's disease patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cerebral Amyloid Angiopathy / physiopathology*
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / pathology
  • Cerebral Hemorrhage / etiology*
  • Contraindications
  • Disease Models, Animal
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / pharmacology
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Mice
  • Mice, Transgenic
  • Middle Aged
  • Thrombolytic Therapy / adverse effects*
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / pharmacology*
  • Tissue Plasminogen Activator / therapeutic use


  • Fibrinolytic Agents
  • Tissue Plasminogen Activator